ICBCCS SSE STAR Biology and Medicine ETF

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

RemeGen Approves 2.5B RMB Cash Management Plan, Invests 453M with HTSC in Fixed Income Products

Baili Tianheng's Innovative Drug SI-B036 Approved for Clinical Trials in Late-Stage Solid Tumors by NMPA

BeiGene's Brukinsa Approved by FDA

Rongchang Biotech Purchases Multiple Wealth Management Products from SPDB Yantai Branch

Belayidiantianheng Receives Approval for Clinical Trials of Iza-bren Combination Therapy

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

CMBC International and DBS Maintain Buy Rating for BeiGene

Citibank Raises BeiGene's US Stock Target Price to $453

Belayzhizun (BeiJing) Q1 Earnings Exceed Expectations

BeiGene Releases Q1 2026 Financial Report and Revises Financial Guidance

Beyterzelk and Amgen Authorized Products Drive First Quarter 2026 Revenue Growth for BeiGene

BeiGene Adjusts 2026 Full-Year Operating Performance Forecast

BeOne Medicines released FY2026 Q1 earnings on May 6 Pre-Market (BJT), actual revenue CNY 10.46 B (forecast CNY 9.93 B), actual EPS CNY 1.0368

BeiGene Secures Global Rights to Huaheng's Tri-Antibody for $20 Million

BrightGene released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 324.93 M, actual EPS CNY 0.02

BeOne Medicines to Release FY2026 Q1 Earnings on May 6 Pre-Market (BJT), Forecast Revenue CNY 9.835 B

BofA Securities Notes BeiGene's Pharmaceutical Sales Growth Maintains Buy Rating

Zelgen released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 905.39 M, actual EPS CNY 2.39

159892

516820

516500

159859

159837

516930

510660

520690

588250

560600

588130

Ab&B Bio-Tech CO., LTD. has begun Phase I and II trials for its recombinant RSV vaccine after receiving approval from China's National Medical Products Administration. The vaccine targets respiratory syncytial virus, crucial for vulnerable populations in China. Despite promising preclinical results, trading of the company's shares remains suspended since April 1, 2026, and there is no guarantee the vaccine will reach the market. Ab&B Bio-Tech focuses on innovative vaccines and has a diverse pipeline, including influenza and rabies vaccines.

Tip Ranks

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Minsheng Royal CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

E Fund CSI 300 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

AB&B BIO-TECH-B

Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended

01177

159929

G Sachs has raised the target price for SBP GROUPto HKD8.05, maintaining a Buy rating following the company's agreement with GlaxoSmithKline (GSK) for exclusive commercialization rights in China for the hepatitis B drug bepirovirsen. The drug, expected to be approved in 2027, aligns with the treatment needs of China's 75 million chronic hepatitis B patients. G Sachs has increased its earnings forecasts for 2027 and 2028 by 1.1% and 1.7%, respectively, reflecting the anticipated sales contribution from bepirovirsen.

AASTOCKS News

SBP GROUP

GlaxoSmithKline plc

Guotai SSE STAR Brand Name Drug ETF

China Universal 800 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Goldman Sachs

GS Hldg R

GSK plc Sponsored ADR

G Sachs Raises SBP GROUP  TP to HKD8.05, Maintains Buy on Introduction of GSK Hepatitis B Drug

02509

603259

WXXWY

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

QYUNS-B

WuXi AppTec

WuXi Biologics

WUXI APPTEC

SKB BIO

WUXI BIO

TEDA BIOMEDICAL

INNOVENT BIO

WUXI XDC

China Universal CNI HK Connect Innovative Drugs Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

HBM Holdings Ltd. announced that its independent non-executive director, Dr. Xiaoping Ye, is under investigation by the China Securities Regulatory Commission for alleged information disclosure violations. The company stated that Dr. Ye does not engage in daily management and will cooperate with regulators. HBM's operations are reported to be normal, with no expected impact from the probe. Shareholders are advised to exercise caution during the inquiry. The latest analyst rating for HBM stock is a Buy, with a price target of HK$17.00.

HBM HOLDINGS-B

Tigermed

TIGERMED

HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations

02616

CStone Pharmaceuticals has launched nationwide supply of its domestically produced pralsetinib capsules in China, enhancing local supply chain for this cancer therapy. The drug's sales surged over 430% year-on-year, with expectations to exceed RMB 300 million in 2026. This move aims to meet rising clinical demand and improve cost efficiency. Pralsetinib is approved for RET fusion-positive non-small cell lung cancer and thyroid cancer, reinforcing CStone's position in precision oncology in the region.

CSTONE PHARMA-B

CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge

LABU

Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News

StockTitan

VanEck Biotech ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares Global Healthcare

BlackRock, Inc.

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

Proshares Ultra Nasdaq Biotech

Proshares UltraShort Nasdaq Biotech

Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News

Coloplast A/S reported a Q2 loss of 971 million Danish kroner, down from a profit of 912 million kroner last year, primarily due to a 3.03 billion kroner impairment loss related to Kerecis. Despite this, revenues rose 2% to 7.08 billion kroner, with organic growth of 6%. The company reaffirmed its FY26 outlook, projecting revenue growth of 3% and adjusted EBIT growth of around 5%. A half-year interim dividend of 5.00 kroner per share will be paid.

rttnews

SPDR S&P Health Equip

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

iShares US Medical Devices

ChinaAMC CSI All Share Health Care Devices ETF

Coloplast A/S Class B

Coloplast Slips To Loss In Q2 On Hefty Charge, Revenues Rise; Confirms FY26 Outlook

SBP GROUPannounced preclinical data for its innovative drug TQF6422 at the 2026 European Congress on Obesity. TQF6422, a fully human monoclonal antibody targeting ActRII A/B, promotes muscle growth and fat reduction. Its in vitro activity exceeds comparable products by over 10 times. In combination with semaglutide, TQF6422 showed significant synergistic effects, increasing fat reduction by 1.5 to 2 times in an obese monkey model, with fat loss comprising 93% of total weight loss.

SBP GROUP  Announces Preclinical Data of Innovative Drug TQF6422 at European Congress on Obesity

Integrated BioPharma, Inc. (OTCQX:INBP) reported a revenue decline of 27.3% for Q1 2026, totaling $10.1 million, compared to $13.9 million in Q1 2025. The company experienced an operating loss of $1.1 million in Q1 2026, contrasting with an operating income of $0.7 million in Q1 2025. For the nine-month period ending March 31, 2026, revenue was $34.1 million, down 15.2% from $40.2 million in the same period last year, with a net loss of $1.5 million. The company attributes the revenue drop to reliance on a few major customers.

iShares US Healthcare Providers

SPDR S&P Health

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026 | INBP Stock News

ZLAB

09688

Zai Lab Ltd (HK:9688) reported Q1 2026 revenues of $99.6 million, impacted by seasonal dynamics and competition for ZEJULA and VYVGART. The company is preparing for the China launch of KarXT for schizophrenia and is undergoing regulatory review for TIVDAK. Positive Phase 3 data for povetacicept and elegrobart were highlighted, along with strong momentum in its R&D pipeline, particularly for zoci in oncology. The latest analyst rating is a Hold with a price target of HK$18.00. Zai Lab focuses on innovative therapies in oncology and immunology, with a market cap of HK$18.31B.

- Zai Lab Ltd reported first-quarter 2026 revenues of $99.6 million, impacted by seasonal dynamics and competition for key drugs.  
- The company is preparing for the China launch of KarXT for schizophrenia and has positive data for its ongoing projects, positioning itself for regional growth.  
- Zai Lab’s strong R&D pipeline includes promising developments in oncology and immunology, maintaining a market cap of HK$18.31 billion with a current analyst rating of Hold at a HK$18.00 price target.

Zai Lab

ZAI LAB

Amgen

Zai Lab Q1 2026 Results Highlight Pipeline Momentum and Upcoming China Launches

ICBCCS SSE STAR Biology and Medicine ETF(588860.SH)

Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended

G Sachs Raises SBP GROUP TP to HKD8.05, Maintains Buy on Introduction of GSK Hepatitis B Drug

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations

CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge

Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News

Coloplast Slips To Loss In Q2 On Hefty Charge, Revenues Rise; Confirms FY26 Outlook

SBP GROUP Announces Preclinical Data of Innovative Drug TQF6422 at European Congress on Obesity

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026 | INBP Stock News

Zai Lab Q1 2026 Results Highlight Pipeline Momentum and Upcoming China Launches